BB Biotech posts CHF 175 million net profit in third quarter of 2026
BB Biotech reported a CHF 175 million net profit for Q3 2026, with NAV up 5.6% in Swiss francs and shares up 6.5%, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swiss investment company BB Biotech AG said its net asset value (NAV) rose 5.6% in Swiss francs during the third quarter of 2026, while its share price gained 6.5% in francs. The quarter brought in a net profit of CHF 175 million, Reuters reported.
The company said it sees selective opportunities among firms whose shares have fallen even though their clinical prospects have not changed.
why it matters
The result matters mainly for investors in biotech funds, as it suggests managers are looking to add exposure to individual stocks after price declines not tied to changes in the companies themselves.
tags
instruments
sources
- BB Biotech Reports Q3 2026 Net Profit CHF 175 Mln — Reuters, 23 October 2026 at 05:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗